

ABL Biotechnologies Limited

Regd. Office: No.71, Nehru Nagar, Industrial Estate, 2nd Link Street, Kottivakkam, Chennai - 600 041
Statement of Standalone/Consolidated Financial Results for the Quarter Ended 31/12/2013

PART I	Particulars	(Rs. in Lakhs)											
		3 months ended		Preceding 3 months ended		Corresponding 3 months ended in the previous year		Year to Date figures for current period ended		Year to Date figures for the previous year ended		Previous Year ended	
		31.12.2013	30.09.2013	31.12.2012	31.12.2012	31.12.2013	31.12.2013	31.12.2012	31.12.2012	31.03.2013	31.03.2013		
	Unaudited standalones	Unaudited consolidated	Unaudited standalones	Unaudited consolidated	Unaudited standalones	Unaudited consolidated	Audited standalones	Unaudited Consolidated	Unaudited standalones	Unaudited Consolidated	Audited standalones	Audited consolidated	
1	Income from operations												
	(a) Net Sales/Income from Operations		0.00	0.00	0.00				0.00	0.00	0.00	0.00	0.00
	(b) Other Operating Income		0.16	0.16							0.65	0.65	0.65
	Total income from operations (net)	0.16	0.16	0.16	0.00	0.00	0.48	0.48	0.00	0.48	0.65	0.65	0.65
2	Expenditure												
	(a) Increase/Decrease in Stock in trade and work in progress												
	b) Consumption on Raw materials												
	c) Product Development Cost												
	d) conversion / other charges												
	e) Purchase of traded goods												
	f) Employee benefits expense										1.50	1.50	1.50
	g) Rent				0.04	0.04	0.04	0.04	0.13	0.13	0.00	0.00	0.00
	h) Travel & Conveyance Expenses				0.37	0.37	0.37	0.36	0.62	0.62	0.03	0.03	0.03
	i) Legal/Consultancy Expenses	0.25	0.04	0.04									
	j) Office Renovation								0.39	0.39			
	k) Bangalore shifting charges				(0.07)	(0.07)	(0.07)				0.01	0.01	0.01
	l) Communication Cost		0.01	0.01	0.02	0.02	0.01	0.01	0.03	0.03	0.00	0.00	0.00
	m) Printing & Stationery				0.08	0.08	0.08		0.11	0.11	0.00	0.00	0.00
	n) RTA/BSE/CDS/NSDL Fees	0.07	0.10	0.10	(0.23)	(0.23)	(0.23)	0.97	0.97	0.72	0.85	0.85	0.85
	o) Instrument maintenance												
	p) Power, Fuel & Gas chgs												
	q) Consumables				(0.75)	(0.75)	(0.75)				0.33	0.33	0.33
	r) Audit Fees				0.06	0.06	0.06	0.09	0.10	0.10	0.16	0.16	0.16
	s) Bank Charges	0.07	0.02	0.02									
	t) Service Cost for labour				(0.02)	(0.02)	(0.02)				0.00	0.00	0.00
	u) Others				1.65	1.65	1.65	6.20	4.75	4.75	6.77	6.77	6.77
	v) Depreciation and amortisation expense	2.20	2.20	2.20	1.22	1.22	1.22	3.68	3.68	3.69	4.92	4.92	4.92
	w) Preliminary expenses written off	1.23	1.23	1.23									
	x) Ope expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)												
	Total expenses	3.82	3.80	3.80	2.37	2.37	11.32	11.32	10.56	10.56	18.47	18.47	18.57

Page 2	ABL Biotechnologies Limited	Statement of Standalone / Consolidated Unaudited / Audited Results for the Quarter Ended 30/09/2013												(Rs. in Lakhs)	
		3 months ended			Preceding 3 months ended			Corresponding 3 months ended in the previous year			Year to Date figures for current period ended			Year to Date figures for the previous year ended	
		31.12.2013		30.09.2013		31.12.2012		31.12.2013		31.12.2012		31.12.2012		31.03.2013	
		Unaudited standalone	Unaudited consolidated	Unaudited standalone	Unaudited consolidated	Unaudited standalone	Unaudited consolidated	Audited standalone	Unaudited consolidated	Unaudited standalone	Unaudited consolidated	Audited standalone	Audited consolidated		
3	Profit / Loss from Operations before other income, finance costs and financial items (1-2)	(3.66)	(3.66)	(3.44)	(3.44)	(2.37)	(2.37)	(10.84)	(10.84)	(10.56)	(10.56)	(17.82)	(17.92)		
4	Other income														
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(3.66)	(3.66)	(3.44)	(3.44)	(2.37)	(2.37)	(10.84)	(10.84)	(10.56)	(10.56)	(17.82)	(17.92)		
6	Finance costs														
7	Profit / (Loss) from ordinary activities before finance costs but before exceptional items (5-6)	(3.66)	(3.66)	(3.44)	(3.44)	(2.37)	(2.37)	(10.84)	(10.84)	(10.56)	(10.56)	(17.82)	(17.92)		
8	Exceptional items - write offs														
9	Profit / Loss from ordinary activities before tax (7+8)	(3.66)	(3.66)	(3.44)	(3.44)	(2.37)	(2.37)	(10.84)	(10.84)	(10.56)	(10.56)	(17.82)	(17.92)		
10	Tax expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
11	Net Profit / Loss from ordinary activities after tax (9-10)	(3.66)	(3.66)	(3.44)	(3.44)	(2.37)	(2.37)	(10.84)	(10.84)	(10.56)	(10.56)	(17.82)	(17.92)		
12	Extraordinary items (net of tax expense Rs. Lakhs)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
13	Net Profit / Loss for the period (11-12)	(3.66)	(3.66)	(3.44)	(3.44)	(2.37)	(2.37)	(10.84)	(10.84)	(10.56)	(10.56)	(17.82)	(17.92)		

Part II	ABL Biotechnologies Limited	Select information for the quarter ended 31/12/2013														
		3 months ended		Preceding 3 months ended		Corresponding 3 months ended in the previous year		Year to Date figures for current period ended		Year to Date figures for the previous year ended		Previous Year ended				
		31.12.2013	30.09.2013	31.12.2013	31.12.2013	31.12.2013	31.12.2013	31.12.2013	31.12.2013	31.12.2013	31.03.2013	31.03.2013				
Unaudited standalone		Unaudited consolidated		Unaudited standalone		Unaudited consolidated		Unaudited standalone		Unaudited consolidated		Audited standalone		Audited consolidated		
A	PARTICULARS OF SHAREHOLDING	Public Shareholding	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000	8151000
		- Number of shares	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%	99.40%
1	- Percentage of shareholding															
2	Promoters and promoter group Shareholding**	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	a) Pledged/Encumbered															
	- Number of shares	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%
	b) Non-encumbered															
	- Number of Shares	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000	49000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%	0.60%

Part II	INVESTOR COMPLAINTS	3 months ended (31/12/2013)
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil

Notes

- (1) Above results were taken on record by the Board of Directors at their meeting held on 10th February 2014
- (2) Previous year/quarter figures have been regrouped where necessary.
- (3) ABL Research Pvt. Ltd. a 100% subsidiary of ABL Biotechnologies started activities in Research Projects effective April 2010 and incurred expenses of Rs. 18.92 Lakhs during April - September 2013 bringing the total expenses in the project to Rs. 68.84 lakhs. These expenses being in the nature of Project expenses are being accumulated and reported under Preliminary Operative expenses.

For ABL Biotechnologies Limited


Managing Director

Place : Chennai

Date : 10. 02. 2014

Limited Review Report

Review Report to ABL Biotechnologies Limited

We have reviewed the accompanying statement of unaudited financial results of ABL Biotechnologies Limited for the period ended from 01.10.2013 to 31.12.2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pratakaran Paul & Co.,
Chartered Accountants

P. Dharmaraj

Dharmaraj
Partner
M. No. 224216



Date : 10.02.2014
Place: Chennai